Please login to the form below

Not currently logged in
Email:
Password:

systemic juvenile idiopathic arthritis

This page shows the latest systemic juvenile idiopathic arthritis news and features for those working in and with pharma, biotech and healthcare.

Roche snags pair of FDA breakthrough designations

Roche snags pair of FDA breakthrough designations

First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green light for rheumatoid arthritis and systemic juvenile idiopathic arthritis in several markets including the US and ... With a rival now on its heels, Roche is

Latest news

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... The European Commission (EC) gave its final assent to Ilaris for the treatment of systemic

  • Novartis lifts 2013 guidance on delay to Diovan generics Novartis lifts 2013 guidance on delay to Diovan generics

    Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis

  • EU approves new use of Roche's RoActemra in children EU approves new use of Roche's RoActemra in children

    Specifically, the EU medicines regulator has given RoActemra (tocilizumab) the green light to treat children with polyarticular juvenile idiopathic arthritis (PJIA) – a rare, chronic and debilitating form of childhood arthritis. ... RoActemra, also

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Ilaris (canakinumab) - which acts as an inhibitor for the cytokine interleukin-1 beta - is now approved as a treatment for active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years ... SJIA is the most aggressive form of juvenile

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics